Low Density Lipoprotein Cholesterol–Lowering Strategies and Population Health
Author:
Affiliation:
1. Department of Medicine I, University Hospital RWTH Aachen, Germany (J.B.).
2. Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, UK (J.B., K.K.R.).
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference5 articles.
1. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe
2. Improving medication adherence in patients with cardiovascular disease: a systematic review
3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
4. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
5. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias;Journal of Clinical Medicine;2024-07-16
2. Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis;Frontiers in Cardiovascular Medicine;2024-06-03
3. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION‐9, ORION‐10 and ORION‐11 Phase 3 randomized trials;Diabetes, Obesity and Metabolism;2024-05-17
4. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention;Atherosclerosis;2024-04
5. An update on inclisiran for the treatment of elevated LDL cholesterol;Expert Opinion on Pharmacotherapy;2024-03-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3